Genprex Inc. (NASDAQ: GNPX)
$2.08
+0.1000 ( +5.05% ) 23.3K
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Market Data
Open
$2.08
Previous close
$1.98
Volume
23.3K
Market cap
$4.32M
Day range
$1.96 - $2.10
52 week range
$1.77 - $42.00
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
def | Proxies and info statements | 5 | Nov 03, 2023 |
8-k | 8K-related | 14 | Oct 23, 2023 |
pre | Proxies and info statements | 4 | Oct 23, 2023 |
8-k | 8K-related | 13 | Sep 25, 2023 |
8-k | 8K-related | 66 | Sep 08, 2023 |
8-k | 8K-related | 13 | Sep 01, 2023 |
8-k/a | 8K-related | 14 | Aug 21, 2023 |
10-q | Quarterly Reports | 43 | Aug 21, 2023 |
nt | Quarterly Reports | 1 | Aug 15, 2023 |
8-k | 8K-related | 19 | Jul 19, 2023 |